SBIR and STTR Success Story for
Reaction Biology Corp

(Information Posted/Updated on 02/24/2011)

Reaction Biology Corp
1 Great Valley Parkway
Suite 2
Malvern, PA  19355

Contact:    Matthew Oristano
Phone:      203-389-7407
Web Site:

Project Title:  Methyltransferase Drug Discovery
Related Award(s):  1R43CA139621
Technology Developed:
The "gold standard" in methyltransferase assays is the tritium radioisotope based assay. Using SBIR grant funding, RBC created a miniaturized version of this assay called Methyltransferase HotSpot, which uses far less enzyme, compound, and radioactive material.

Key Words:  tritium, 3h, assay, methyltransferase, epigenetic, drug discovery.
Uses of Technology/Products/Service:
A new frontier in drug discovery research is epigenetics, whereby various human enzymes act to turn gene functions on and off. A key group of enzymes with epigenetic effects are methyltransferases. By finding chemicals that inhibit these enzymes, drugs for a wide array of human diseases could possibly be found. Up until now, the main way to discover compounds that would inhibit methyltransferases was a very cumbersome tritium assay, using an isotope of hydrogen. RBC has made the assay much faster and less expensive, making the early stage of drug discovery in this area much more efficient.

Benefit to Company:
RBC is the only contract research company offering a methyltransferase assay service. RBC has successfully launched its Methyltransferase HotSpot assay service to the industry, and in spite of the very early stage in this area, has begun serving large pharmas, biotechs, non-profit institutions and universities. RBC expects to be the leader in early stage epigenetic research services to the drug discovery industry.

How Product Was Commercialized:
Due to the lack of availability of methyltransferase screening resources, RBC was able to commercialize the product with Google advertising, conference attendance and email marketing. That plus word of mouth and repeat business have led to a customer list of over 150 for RBC's other services that can be marketed for Methyltransferase HotSpot.

Estimated Future Annual R&D and/or Sales from this Project:   $>20 million